Oct 6, 2017 8:25 am EDT Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
Oct 4, 2017 8:45 am EDT Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
Sep 28, 2017 8:32 am EDT Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
Aug 29, 2017 9:05 am EDT Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
Aug 15, 2017 8:25 am EDT Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
Jul 25, 2017 8:05 am EDT Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
Jul 18, 2017 8:05 am EDT Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
Jun 29, 2017 8:15 am EDT Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
